COMPARE · Data as of August 27, 2026
DYN vs HALO
Verdict: Side-by-side breakdown using the Bull Rankings model. DYN scored 9.8, HALO scored 78.7 — HALO leads.
Compare another set
DYN
Dyne Therapeutics, Inc.
9.8
$26.09 · $4.9B
fundamentals as of
Score gap
68.9
HALO leads
HALO
Halozyme Therapeutics, Inc.
78.7
$108.63 · $12.3B
fundamentals as of
At a glance · who leads each dimension, on the model's own rules
- Highest qualityHALO96 / 100
- Largest discount to fair valueHALO-38%
Side by side · every name on one set of axes
The model, pillar by pillar (0–100 each)
DYN
stronger →← stronger
HALO
18
Qualityreturns · margins · balance sheet
96
10
Growthrevenue & earnings expansion
97
5
Valuevaluation vs sector peers
53
HALO is stronger on 3 of 3 pillars.
Fundamentals, head-to-head
DYN
HALO
-$480mF
FCF
$806mC+
—
Rev
+41.2%A
0.33B
D/E
—
—
PEG
1.51C+
—
P/E
31.9xB
Winner per row is the stronger grade; where grades tie, the better figure breaks it. A true tie or a missing value shows no highlight.
Valuation · DCF cross-check
DYN
HALO
—
Price vs fair valuelower is cheaper
38% below
—
Growth the price implies10-yr FCF · lower = less priced in
~1%/yr
—
1-yr DCF upside
+29%
—
5-yr DCF upside
+62%
—
10-yr DCF upside
+128%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
DYN
Why this score
- Diluting shareholders
HALO
Why this score
- Buying back stock
- Durable high returns
The companies
DYNDyne Therapeutics, Inc.
Why now
Biotechnology · market cap $4.9b. 4% off the 52-week high of $27.30. 15 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $39.40 (implying +51% upside).
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$480m) — capital raises or debt issuance likely required; dilution / leverage risk. ROE -74% is below the long-run sustainable threshold of ~10% — capital efficiency would need to improve for the equity base to compound at the market rate. FDA approval timing — regulatory schedules slip routinely; every quarter of delay pushes commercialization revenue out by the same amount and tests the cash runway.
HALOHalozyme Therapeutics, Inc.
Why now
Biotechnology · market cap $12.3b. Trading near 52-week high of $109.65 — momentum setup, limited technical margin of safety. Revenue growing +41% — in hypergrowth territory. 9 sell-side analysts rate this a Buy with a mean 1-yr target of $99.56 (implying -8% upside).
Moat
Net margin 25% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. FCF converts 195% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trading within 1% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. Trailing P/E 32x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where DYN and HALO diverge
On the headline score the gap is 68.9 points in favor of HALO. The widest single difference is Growth, where HALO leads by 87.0 points.
- GrowthDYN 10.0 · HALO 97.0HALO +87.0
- QualityDYN 17.5 · HALO 95.7HALO +78.2
- ValueDYN 5.4 · HALO 52.6HALO +47.2
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.